Skip to main content

Table 4 Effect of weight on clearance and volume of distribution

From: Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial

Weight (kg) CL/F (L/h) % of reference V/F (L) % of reference
5 305 10.9 853 22.0
15 766 27.5 1601 41.4
25 1176 42.2 2145 55.4
70a 2789 100.0 3870 100.0
  1. CL/F apparent clearance, V/F apparent volume of distribution
  2. aReference weight (adult male patient)